The clinical problems mentioned by Xiao Ming are actually the final stage of testing experimental results.

In theory, technology is successful in the laboratory, and it cannot be proved that clinical practice will definitely succeed.

It is quite difficult to conduct clinical experiments in Xia Kingdom!

Not to mention all kinds of complicated procedures, whether or not you can obtain cooperation from the hospital is also a question mark.

Moreover, in the field of medicine, clinical experiments not only involve medical technical issues, but also patient life safety and ethical issues.

After all, Pangu Technology's life science laboratory is a private research institute for private enterprises. In the field of life science research, most of the keys are in the country, and in the hands of scientific research institutions such as Yenching University and Jiangcheng University.

When Xiao Ming mentioned clinical problems, Gao Siqi also fell into deep thought.

"We don't have special hospitals, and we don't even have the qualifications for clinical trials," she said.

"If you apply now, how long will it take?" Xiao Ming said after thinking for a while.

Xiao Ming is not an expert in medical experiments, so he raised this question.

Zheng Xuanyu is an expert in this field, saying: "If you have a hospital background or a scientific research institution that cooperates with the hospital, the time should be faster, the application should be as short as three to five years, and the long as ten to twenty years. This is true for Xia and the United States. After all, a new drug and new treatment should be ensured that every indicator is absolutely safe from the success of the experiment to the launch of the market. But you are like this now..."

Zheng Xuanyu said: "It is obviously impossible now. There are analysis reports before the drug or treatment methods enter clinical experiments. Secondly, there must be complete vegetative medical experiments, and finally human clinical experiments. Human clinical experiments have four stages, and this process is quite long."

Zheng Xuanyu took the United States' anti-cancer targeted drug as an example and said: "Now we see on the market that the latest anti-cancer drug in the United States was actually launched more than ten or twenty years ago! The same is true in Xia Country. Ordinary drugs have been going for at least three or four years from research and development to market. Drugs similar to anti-cancer drugs that concern the safety of people's lives, have also gone for ten years!"

Xiao Ming knew that this was a law and a provision, but he also expressed serious incomprehension.

Take patients with advanced cancer as an example. They are already in advanced cancer and are counting their fingers to live. If there is really a special medicine, it is too late to take it immediately. How can there be any concerns about the crisis and life safety?

The premise here is that this drug is indeed effective!

Xiao Ming said speechlessly: "For ten to twenty years of listing approval time, I don't know how many patients have no chance to wait for such a long time."

Gao Siqi also sighed.

Xiao Ming found it a little funny at this time. The laboratory for gene expression regulation was completed completely in accordance with Pansha Technology's experimental guidelines. The results were expected and it was definitely possible to treat cancer.

A method that has long been proven to have no side effects at all, and has to go through a long approval process here, which is indeed a bit dramatic.

But this is also normal. Xiao Ming can't go to the relevant department with the treatment plan and say that there is absolutely no problem with this technology, you have to believe me.

Zheng Xuanyu proposed a feasible plan. She said: "We have two plans. One is to apply for a clinical trial license according to the conventional steps and wait for approval from relevant departments. The other is to cooperate with the hospital to recruit patients who voluntarily try new drugs, but the latter has a relatively high risk."

"What does the last plan mean? Can you explain it in detail?" Gao Siqi asked.

Zheng Xuanyu nodded and said, "In fact, not only in Xia Country, but also in the United States, many of the first anti-cancer drugs or procedures have not been completed, or they are still lacking, and have not obtained a marketing license. The market calls these drugs defective drugs. However, the market has a strong demand for these imperfect drugs."

Zheng Xuanyu took the United States, which has the most advanced and complete cancer medical technology, as an example, and continued: "Many research institutions in the United States cooperate with hospitals to provide patients with 'defective' drugs. Even if these drugs are defective, they can relieve the patient's pain and prolong the patient's life. People are already on the verge of death, so they can be considered as a dead horse as a living horse."

Gao Siqi said: "You are talking about the United States, and this is Xia Country. Is this okay?"

Before Zheng Xuanyu answered this question, Gong Luyue interrupted and said, "There are more defective drugs in Xiaguo, such as folk anti-cancer secret recipes, traditional Chinese medicine methods, etc., which of these folk Chinese medicine and prescriptions have been approved? Anyway, patients are in a hurry to seek medical treatment. In the face of life and death, it is great that they can have a glimmer of hope to be alive. If you cure it, it is the credit of these folk miracle doctors. If you eat it, you will be cancerous."

Gong Luyue accidentally revealed the darkest and most absurd side of Xia Guo Medical. The patients she mentioned were definitely not a minority. Most of them chose to believe in the so-called traditional folk prescription conservative treatment after being consulted in large hospitals, and the final outcome of these patients was death.

Therefore, approval and clinical experiments are all empty talk.

After Gong Luyue's speech was published, Xiao Ming also felt deeply helpless.

Zheng Xuanyu continued: "I just took the United States as an example, but in fact, the same is true for Xia. Many universities, official and unofficial scientific research institutions have cooperated with hospitals to promote defective drug treatment to patients. These drugs are not approved for marketing, and are all in experiments. However, the drugs are more or less effective and can extend the patient's survival expectations."

"In the treatment of defective drugs, the hospital is just an intermediate platform and does not guarantee any guarantee to patients. The pharmaceutical company signs an agreement with the patient, which will not guarantee the survival rate of patients. However, they are in the late stage of cancer and are about to die. Many patients still try new drugs that have not been launched. This method gives patients the opportunity to survive and also gives pharmaceutical companies the opportunity to informal clinical research. After all, from the perspective of medical experiments, the time and funds spent on formal clinical medical experiments are quite huge, and few companies can afford it."

Zheng Xuanyu is worthy of being an expert. She has a very thorough understanding of medical experiments. "If these informal clinical experiments are proven to be effective, the medical laboratory will apply for superior funds to continue research with sufficient data, or simply sell the experimental projects to more professional and powerful pharmaceutical companies, and these pharmaceutical companies will follow complex procedures such as clinical experiments, approvals, etc. This is the current situation of global pharmaceutical research."

"So, it depends on how you decide." Zheng Xuanyu looked at Xiao Ming.m.
Chapter completed!